The analysis, conducted according to PRISMA 2020 standards, drew its evidence from the major Phase 3 programs that defined the modern incretin era: SURMOUNT, testing tirzepatide; STEP, testing injectable semaglutide; SCALE, testing liraglutide 3.0 mg; and OASIS, testing oral semaglutide. From an initial pool of 878 records, independent reviewers narrowed the field to 19 randomized controlled trials meeting strict criteria, including a minimum duration of 12 weeks and standardized body composition or nutritional laboratory measurements. High-potency therapy was defined as any agent or dose producing at least 10 percent mean total body weight reduction, a threshold met by all tirzepatide doses, injectable semaglutide at 1.0 mg or above, and oral semaglutide 50 mg. Liraglutide 3.0 mg was classified as a moderate-potency comparator but retained because the SCALE program remains the only Phase 3 dataset with longitudinal pancreatic enzyme measurements.

The mechanistic foundation of the findings lies in the sheer magnitude of caloric suppression these drugs produce. Once-daily oral semaglutide 50 mg reduced energy intake by a relative 39.20 percent by week 20, translating to a deficit of roughly 1009 kilojoules, about 241 calories, during a single ad libitum lunch compared with placebo. Across the synthesized trials, metabolic models estimated daily energy deficits reaching 1200 kilocalories from baseline, while tirzepatide 15 mg produced a consistent 348.40 kilocalorie per day reduction. Meta-analysis of continuous intake data confirmed this suppression was statistically robust. Critically, these deficits occurred alongside shifts in food preference: participants on tirzepatide showed significant decreases in 10 of 12 food preference categories, blunting desire for high-fat and high-sugar items. The hedonic blunting that helps patients eat less may simultaneously suppress the biological hunger signals that normally correct for emerging nutrient gaps.

Body composition data revealed a second dimension of concern. Across drug classes, fat-free mass, the non-adipose component of body weight that includes muscle, bone, organs, and fluids, declined significantly. Tirzepatide 15 mg was associated with a mean fat-free mass reduction of 1.60 kg, representing 14.30 percent of total weight lost, while semaglutide 1.0 mg produced a 0.80 kg decline constituting 11.60 percent of weight reduction. The researchers emphasize that fat-free mass is not synonymous with skeletal muscle mass, and only one mechanism-of-action study reported appendicular lean mass as a muscle proxy. Even so, the proportional loss of lean tissue raises the prospect of sarcopenic obesity, a condition combining reduced muscle mass with metabolic dysfunction. The risk is sharpened by the finding that 7.26 percent of participants crossed a body mass index below 22 kg/m2, a threshold at which clinical protocols recommend modifying intake to prevent physical frailty.

The contrast between clinical reporting and laboratory reality forms the analytical centerpiece of the review. Pooled analysis of MedDRA-coded malnutrition events across the SURMOUNT 1-4 trials produced a non-significant risk ratio of 2.38, suggesting standard adverse event capture missed most nutritional deterioration. Total lymphocyte count below 910 per microliter, a marker independently associated with impaired immune function, delayed wound healing, and increased infection susceptibility, appeared in 2.90 percent of active therapy participants, nearly double the placebo rate, with a statistically significant risk ratio of 1.64. Meanwhile, 0.38 percent of tirzepatide-treated participants reached an underweight classification during treatment, and investigator-reported vitamin deficiencies involving vitamin D, B12, and folate occurred in 0.99 percent, though none of the original protocols screened for these systematically at predetermined intervals.

Secondary metabolic stressors add another layer of physiological complexity. Pooled SCALE data documented a mean 31 percent increase in pancreatic lipase and 7 percent increase in amylase following liraglutide treatment, elevations that appeared early, persisted during therapy, were dose-independent, and reversed upon drug cessation. Although 12 cases of acute pancreatitis were confirmed in liraglutide arms, a 0.4 percent incidence, the positive predictive value of enzyme elevations alone was below 1 percent, indicating these biomarkers more likely represent subclinical pancreatic stress than acute inflammation. Whether comparable enzyme dynamics occur with tirzepatide or injectable semaglutide remains unknown, because neither the SURMOUNT nor STEP programs included pancreatic enzyme monitoring. Persistent subclinical pancreatic stress could theoretically introduce a malabsorptive component, potentially compromising fat-soluble vitamin status even in patients with adequate intake.

Individual variability in baseline physiology may determine who is most vulnerable. Deep-phenotyping research describes a ‘Calories to Satiation’ trait ranging from 140 to 2166 kilocalories among adults with obesity, and high-potency incretins may amplify this gut-brain axis signal to its maximum effect. People who already reach satiation at low caloric intakes could ‘overshoot’ intended restriction, a concern compounded by sex differences, since women generally reach satiation at lower energy intakes than men. In trials with predominantly female enrollment, such as SURMOUNT-1 at 67 percent and STEP 1 at 74 percent female, the observed magnitude of lean mass loss may partly reflect this lower baseline caloric threshold. Bone health introduces a further unmeasured dimension: rapid weight loss removes the mechanical loading stimulus that sustains bone mineral density in obesity, and bariatric surgery studies document significant bone loss within 12 to 24 months. No included trial measured bone density, leaving the skeletal consequences of drug-induced weight loss entirely unquantified.

To translate these findings into clinical practice, the researchers propose a Tiered Stepped-Care Algorithm built on the 1200 kilocalorie daily deficit as the mechanistic anchor. Step one mandates baseline screening for albumin, total lymphocyte count, and vitamin D to identify pre-existing vulnerabilities. Step two requires periodic monitoring of the deficit threshold alongside body composition shifts to detect excessive lean mass attrition. Step three activates intensive intervention, with immediate referral for Medical Nutrition Therapy, when serum albumin falls below 3.3 g/dL or total lymphocyte count drops below 910 per microliter. The framework mirrors nutritional oversight long considered standard for bariatric surgery patients, a population whose weight loss trajectories are comparable in magnitude to those produced by maximum-dose tirzepatide, which achieved 22.5 percent total body weight loss over 72 weeks in SURMOUNT-1.

The authors acknowledge important limitations. The original Phase 3 programs were designed to demonstrate weight loss efficacy and cardiometabolic safety, not nutritional outcomes, so reliance on post-hoc analyses likely underestimates true malnutrition prevalence. The 12-week minimum duration criterion may have excluded shorter mechanistic studies, the predominantly East Asian population in SURPASS-AP-Combo, with lower baseline body mass indices, limits generalizability to Western cohorts, and publication bias could not be excluded from secondary endpoints. Quality assessment using the Cochrane Risk-of-Bias tool found low risk across all major domains for the included programs, and Egger regression detected no significant publication bias for the primary outcome. Future trials, the researchers argue, should incorporate pre-specified dual-energy X-ray absorptiometry monitoring, serum micronutrient panels, fecal elastase testing, head-to-head comparisons in adults aged 65 and older with sarcopenia and bone density as co-primary outcomes, and follow-up of at least two years. Sustained weight reduction remains a legitimate therapeutic goal, the analysis concludes, but the data suggest it should no longer be pursued without the nutritional surveillance needed to protect the physiological integrity of the millions of patients now taking these medications.

Subject of Research: Systematic review and meta-analysis of malnutrition risk, energy restriction, and lean mass loss in high-potency incretin therapy

Article Title: A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy

Article References: Ampofo, E., Apprey, C., Amoako, M., & Turkson, F. D. (2026). A Systematic Review and Meta‐Analysis of Malnutrition and Metabolic Failure in High‐Potency Incretin Therapy. Obesity Science & Practice, 12(5), Article e70188. https://doi.org/10.1002/osp4.70188

Image Credits: AI Generated

DOI: 10.1002/osp4.70188

Keywords: incretin therapy, semaglutide, tirzepatide, liraglutide, malnutrition, fat-free mass, weight loss, obesity, GLP-1 receptor agonists, nutritional monitoring, sarcopenia, meta-analysis

The mechanistic foundations of the three drugs explain much of their divergent behaviour. Semaglutide is a human GLP-1 analog with 94 percent sequence identity to the native hormone, engineered with an Aib substitution at position 8 to resist degradation by the enzyme DPP-4 and a C18 fatty diacid side chain at position 26 that binds albumin and extends its half-life to roughly seven days. Liraglutide, with 97 percent homology, carries a shorter C16 palmitic acid chain that yields a half-life of about 13 hours, confining it to once-daily injection. Tirzepatide, a 39-amino-acid synthetic ‘twincretin’, activates both the GIP and GLP-1 receptors and carries a C20 fatty diacid moiety that prolongs systemic exposure to approximately five days. These structural choices dictate dosing convenience, adherence and, ultimately, how patients experience therapy.

Formulation differences add a practical dimension to drug selection. Semaglutide is the only agent in the class available as an oral tablet, made possible by the absorption enhancer SNAC, though oral bioavailability is only about one percent and the tablet must be taken fasting with water only. Subcutaneous semaglutide achieves roughly 89 percent bioavailability. Liraglutide requires daily subcutaneous injection, which may deter some patients, while tirzepatide is delivered exclusively as a once-weekly autoinjector. Real-world data show semaglutide achieves approximately 40 percent treatment persistence at one year, higher than liraglutide, and tirzepatide’s weekly dosing is expected to support strong adherence, though long-term real-world outcomes remain pending. Notably, liraglutide is the only one of the three approved for adolescents with both type 2 diabetes and obesity.

On glycaemic control, the review’s synthesis of trial data reveals a clear hierarchy. Subcutaneous semaglutide at 0.5 to 1.0 mg reduced HbA1c by 1.3 to 1.8 percent across the SUSTAIN program, outperforming placebo, sitagliptin, exenatide and basal insulin, while oral semaglutide achieved reductions of 1.3 to 2.0 percent in the PIONEER trials, edging out subcutaneous liraglutide 1.8 mg in PIONEER 4. Liraglutide, tested in the LEAD program at 1.2 and 1.8 mg, produced HbA1c reductions of 0.7 to 1.5 percent. Tirzepatide, however, set a new benchmark: in SURPASS-2, doses of 5, 10 and 15 mg lowered HbA1c by approximately 2.01, 2.24 and 2.30 percent respectively, surpassing semaglutide 1 mg, which achieved 1.86 percent. Pooled analyses indicate more than 90 percent of tirzepatide recipients reached the HbA1c target below 7.0 percent.

Weight outcomes follow a similar pattern. Semaglutide 2.4 mg weekly produced mean weight losses of up to 14.9 percent at 68 weeks in the STEP program and 10.2 percent over four years in the SELECT trial, accompanied by a 7.7 cm reduction in waist circumference. Liraglutide at 3.0 mg daily achieved approximately 4.91 kg of weight loss in meta-analysis, with BMI declines and waist reductions around 3.55 cm. Tirzepatide again led the field: SURPASS trials recorded weight reductions ranging from 5.3 to 17.1 kg depending on dose and comparator, and in the SURMOUNT-4 trial participants with obesity maintained mean reductions of approximately 20.9 percent at 88 weeks. A SURPASS-3 substudy further showed tirzepatide reduced hepatic fat and visceral adipose tissue, with waist circumference falling by up to 18.5 cm at the highest dose.

Lipid modulation, a subtler but clinically relevant domain, also favoured the dual agonist. Semaglutide produced modest reductions of roughly 3 to 6 percent in total cholesterol, 5 to 10 percent in LDL cholesterol and 10 to 15 percent in triglycerides, with slight HDL increases, mechanisms attributed to reduced free fatty acid influx to the liver and enhanced lipoprotein lipase activity. Liraglutide showed mild improvements, particularly in triglycerides and apolipoprotein B, with dose-dependent variability. Tirzepatide delivered the most pronounced effects: meta-analytic estimates showed triglyceride reductions of 13 to 22 percent, total cholesterol reductions of roughly 5 to 7 percent, and HDL increases of 4 to 7 percent, alongside reductions in large triglyceride-rich lipoproteins and small LDL particles. The authors caution, however, that these are surrogate markers whose translation into fewer cardiovascular events remains unproven.

Where hard clinical outcomes exist, the picture becomes more differentiated. In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide reduced three-point major adverse cardiovascular events—cardiovascular death, nonfatal myocardial infarction and nonfatal stroke—by 26 percent, with post hoc analyses suggesting a roughly 35 percent reduction in stroke incidence, the strongest cerebrovascular signal in the class. Liraglutide, in the landmark LEADER trial, achieved a 13 percent MACE reduction driven primarily by significant reductions in cardiovascular death, making it particularly relevant for patients whose dominant risk is mortality. Tirzepatide has not yet completed a dedicated outcomes trial, but a pre-specified meta-analysis of pooled SURPASS data, including the high-risk SURPASS-4 cohort, reported a 27 percent relative risk reduction in three-point MACE and a 46 percent reduction in four-point MACE—promising signals awaiting confirmation from the ongoing SURPASS-CVOT.

Kidney outcomes reveal mechanistic distinctions with direct clinical implications. Semaglutide cut the risk of new or worsening nephropathy by 36 percent in SUSTAIN-6, slowed eGFR decline in pooled analyses, and extended renal protection to non-diabetic individuals with cardiovascular disease in the SELECT trial, suggesting partially glucose-independent benefit. Liraglutide reduced nephropathy risk by 22 percent in LEADER, but its effect appears largely mediated by improved glycaemic control and blood pressure rather than direct nephroprotection. Tirzepatide, studied in SURPASS-4’s chronic kidney disease cohort, attenuated eGFR decline and reduced macroalbuminuria across all doses, and causal mediation analysis indicated that only 40 to 60 percent of the renal benefit was explained by traditional factors such as HbA1c, blood pressure and weight—implying a substantial glucose-independent component that may make it especially valuable for patients with diabetic kidney disease.

Safety profiles across the class are broadly favourable, dominated by gastrointestinal effects. Nausea, vomiting and diarrhoea are common with all three agents, typically arising during dose escalation and subsiding within four to eight weeks with gradual titration. Tirzepatide produces the highest frequency and severity of gastrointestinal events, including constipation, likely reflecting its GIP receptor activity, followed by semaglutide and then liraglutide, which tends to cause milder, more gradual symptoms. Gallbladder events such as cholelithiasis have been observed with all agents, largely associated with rapid weight loss, and pancreatitis is rare. Hypoglycaemia is uncommon unless the drugs are combined with insulin or sulfonylureas. All three are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. In renal impairment, tirzepatide maintains stable pharmacokinetics even in dialysis patients, an advantage over semaglutide and liraglutide, which require caution in end-stage renal disease.

The review’s overarching conclusion is a call for calibrated clinical judgement rather than a declaration of winners. Tirzepatide demonstrably offers the greatest HbA1c and weight reductions, semaglutide combines substantial efficacy with formulation flexibility and the best stroke evidence, and liraglutide provides a proven mortality benefit with the broadest paediatric indication. Yet because every comparison in the analysis is indirect—drawn from separate trials with different populations, comparators and endpoints—the authors insist the findings should be treated as hypothesis-generating, not definitive proof of superiority. They identify direct head-to-head trials, particularly tirzepatide versus higher-dose semaglutide, long-term cardiovascular and renal outcome data for tirzepatide, and evidence in underrepresented populations as critical gaps. Until those trials report, treatment decisions must remain individualized, weighing comorbidities, renal function, tolerability, dosing preferences and each patient’s therapeutic priorities.

Subject of Research: Comparative cardiometabolic effects of the incretin-based therapies semaglutide, liraglutide and tirzepatide in type 2 diabetes and obesity

Article Title: Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

Article References: Bawadi, H., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026). Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. Endocrinology, Diabetes & Metabolism, 9(5), Article e70338. https://doi.org/10.1002/edm2.70338

Image Credits: AI Generated

DOI: 10.1002/edm2.70338

Keywords: semaglutide, liraglutide, tirzepatide, GLP-1 receptor agonists, type 2 diabetes, obesity, HbA1c, weight loss, cardiovascular outcomes, renal function, lipid profile, incretin therapies